secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2026-05-14T12:05:15+00:00
Accession:  0001493152-26-022877
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucid Diagnostics Q1 2026: Processed 3,177 EsoGuard tests, revenue $1.3M, net loss $23.6M
--------------------------------------------------------------------------------

- Processed 3,177 EsoGuard tests in Q1, generating $1.3M in revenue; operating expenses $13.4M including $1.4M stock comp.
- GAAP net loss attributable to common stockholders $23.6M ($0.17 per share); non-GAAP adjusted loss $10.5M ($0.07 per share).
- Ended Q1 with $27.9M cash; proforma cash $45M after $17M public offering, extending runway into 2027.
- Expects Medicare coverage as key milestone; preview of upcoming guideline update recommending EsoGuard as only non-endoscopic test.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000149315226022877/0001493152-26-022877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000149315226022877/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-022877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer